Wanbury has acquired 51% stake in Doctors Organic Chemicals (DOCL).According to a release issued by Wanbury to the BSE today, DOCL has a large USFDA approved facility, and is engaged in selling active pharmaceutical ingredients (APIs) in the US and Europe. "The stake was acquired from the existing promoters of DOCL in an all-cash deal at an enterprise value of approximately Rs 37 crore," the release added.
